AURA vs GLUE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AURA Captures Institutional Edge (3โ1 Pillars ยท 3โ7 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Aura Biosciences, Inc. Common Stock (AURA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GLUE counters with relative strength in Valuation. Fundamentally, AURA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus GLUE at 10.0x Forward P/E and -214.5% operating margin (+325.8% YoY). In options structure, AURA sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro) against GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AURA | GLUE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $728.6M | $795.5M | Larger Scale | GLUE |
| Trailing P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | GLUE |
| Forward P/E Ratio Valuation | N/M | 10.0x | Lower Multiple | GLUE |
| Revenue Growth (YoY) Growth | +0.0% | +325.8% | Higher Growth | GLUE |
| Operating Margin (TTM) Profitability | 0.0% | -214.5% | Higher Margin | AURA |
| Net Profit Margin Profitability | 0.0% | -186.2% | Higher Margin | AURA |
| Return on Equity (ROE) Capital Efficiency | -61.7% | -35.3% | Higher ROE | GLUE |
| 52-Week Range Position Momentum | 52% ($5โ$10) | 1% ($9โ$26) | Stronger Trend | AURA |
| Beta / 30D Volatility Risk Regime | 0.92ฮฒ ยท 75% Vol | 0.94ฮฒ ยท 53% Vol | Lower Realized Risk | GLUE |
| Unified Institutional Score Composite Signal | 31.1 / 100 (SELL) | 43.5 / 100 (HOLD) | Higher Composite | GLUE |